The Oxford University is undertaking a follow-on study to a Phase 1 study involving the two viral vectored Ebola vaccines Ad26-ZEBOV and MVA-BN-Filo. The aim of this study is to investigate the persistence of the vaccine induced immune response at 24-30 and 36-42 months following primary vaccination.